Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 2:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 95 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: AbobotulinumtoxinA dose 2 Clear all
Completed Phase 3 Interventional Results available

BOTOX® Open-Label Treatment in Pediatric Lower Limb Spasticity

NCT01603641
View directory record Official record
Conditions
Pediatrics, Muscle Spasticity, Cerebral Palsy
Interventions
Botulinum Toxin Type A
Biological
Lead sponsor
Allergan
Industry
Eligibility
2 Years to 17 Years
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
26
States / cities
Pasadena, California • Pomona, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Oct 2, 2026, 2:27 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Clinical Trial To Evaluate ANT-1207 In Subjects With Crow's Feet

NCT01358695
View directory record Official record
Conditions
Lateral Canthal Lines, Crow's Feet
Interventions
ANT-1207, Botulinum Toxin Type A
Biological
Lead sponsor
Anterios Inc.
Industry
Eligibility
30 Years to 70 Years
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
6
States / cities
Birmingham, Alabama • Miami Beach, Florida • West Palm Beach, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2013 · Synced Oct 2, 2026, 2:27 AM EDT
Completed Phase 2 Interventional Results available

Clinical Trial To Evaluate ANT-1207 In Participants With Primary Axillary Hyperhidrosis

NCT02479139
View directory record Official record
Conditions
Hyperhidrosis
Interventions
Vehicle, ANT-1207
Biological
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 70 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
19
States / cities
Hialeah, Florida • Miami, Florida • Pinellas Park, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2017 · Synced Oct 2, 2026, 2:27 AM EDT
Completed Phase 2 Interventional Results available

A Study To Assess the Adverse Effects and Change in Condition of OnabotulinumtoxinA X Injection in Adult Participants With Forehead Lines

NCT05152576
View directory record Official record
Conditions
Forehead Lines
Interventions
OnabotulinumtoxinA X, Placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
8
States / cities
Newport Beach, California • Mount Kisco, New York • Rochester, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Oct 2, 2026, 2:27 AM EDT
Recruiting Phase 4 Interventional

Effects of DaxibotulinumtoxinA for Blepharospasm and Hemifacial Spasm

NCT06195241
View directory record Official record
Conditions
Benign Essential Blepharospasm, Hemifacial Spasm
Interventions
DaxibotulinumtoxinA
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 2, 2026, 2:27 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A 4-Arm Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults

NCT01124552
View directory record Official record
Conditions
Lateral Canthal Lines, Crow's Feet, Facial Wrinkles
Interventions
RT001 Botulinum toxin type A (Dose A), RT001 Botulinum Toxin Type A (Dose B), Vehicle, Placebo
Drug · Other
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Jan 30, 2014 · Synced Oct 2, 2026, 2:27 AM EDT
Terminated Phase 4 Interventional

Tandem OnabotulinumtoxinA Galcanezumab Emerging Therapeutic Headache Elimination Research Study

NCT05492695
View directory record Official record
Conditions
Migraine
Interventions
Galcanezumab, Placebo
Drug · Other
Lead sponsor
Diamond Headache Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 29, 2023 · Synced Oct 2, 2026, 2:27 AM EDT
Completed Phase 2 Interventional Results available

Botulinum Toxin Type A (AGN-151607) for the Prevention of Post-operative Atrial Fibrillation in Adult Participants Undergoing Open-chest Cardiac Surgery (NOVA)

NCT03779841
View directory record Official record
Conditions
Post-Operative Atrial Fibrillation
Interventions
AGN-151607, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
55 Years to 90 Years
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
19
States / cities
Stanford, California • New Haven, Connecticut • Washington D.C., District of Columbia + 16 more
Source: ClinicalTrials.gov public record
Updated May 14, 2024 · Synced Oct 2, 2026, 2:27 AM EDT
Completed Phase 2 Interventional Results available

ET-01 in Subjects With Lateral Canthal Lines

NCT03326856
View directory record Official record
Conditions
Lateral Canthal Lines, Crow's Feet
Interventions
botulinum toxin, Type A, Vehicle
Biological
Lead sponsor
Eirion Therapeutics Inc.
Industry
Eligibility
25 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Cary, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Oct 2, 2026, 2:27 AM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate Effects of DYSPORT® Injected in Lower and Upper Limb Combined With Guided Self-Rehabilitation Contract (GSC)

NCT02969356
View directory record Official record
Conditions
Spastic Hemiparesis
Interventions
Botulinum toxin type A, GSC
Biological · Other
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
6
States / cities
Kansas City, Kansas • Pittsburgh, Pennsylvania • Charleston, South Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Oct 2, 2026, 2:27 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety Study of Two Repeat Doses of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults

NCT01124565
View directory record Official record
Conditions
Lateral Canthal Lines, Crow's Feet, Facial Wrinkles
Interventions
RT001
Drug
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
3
States / cities
Birmingham, Alabama • San Diego, California • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 17, 2014 · Synced Oct 2, 2026, 2:27 AM EDT
Withdrawn Phase 2 Interventional

A Study to Evaluate Adverse Events and Effectiveness of OnabotulinumtoxinA in Participants Undergoing Open Abdominal Ventral Hernia Repair for the Achievement of Primary Fascial Closure Without the Use of Component Separation Technique

NCT05606757
View directory record Official record
Conditions
Ventral Hernia, Abdominal Hernia
Interventions
BOTOX Dose A, Placebo for BOTOX, BOTOX Dose B, BOTOX Dose C
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Mineola, New York • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 2, 2026, 2:27 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Dose Finding Study In Subjects With Crow's Feet

NCT01951742
View directory record Official record
Conditions
Lateral Canthal Lines, Crow's Feet
Interventions
ANT-1401, Vehicle
Biological
Lead sponsor
Anterios Inc.
Industry
Eligibility
30 Years to 60 Years
Enrollment
145 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
10
States / cities
Miami, Florida • Pinellas Park, Florida • West Palm Beach, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 29, 2014 · Synced Oct 2, 2026, 2:27 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.

NCT04752774
View directory record Official record
Conditions
Spasticity
Interventions
Corabotase, Placebo, Dysport
Biological · Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years to 70 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
5
States / cities
Downey, California • Overland Park, Kansas • Farmington Hills, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 2, 2026, 2:27 AM EDT
Completed Phase 3 Interventional Results available

Anticholinergic vs. Botox Comparison Study

NCT01166438
View directory record Official record
Conditions
Urge Urinary Incontinence, Overactive Bladder
Interventions
Botulinum toxin A (Botox A®), Solifenacin 5mg, Solifenacin 10mg, Trospium chloride
Drug
Lead sponsor
NICHD Pelvic Floor Disorders Network
Network
Eligibility
21 Years and older · Female only
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
11
States / cities
Birmingham, Alabama • La Jolla, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 2, 2018 · Synced Oct 2, 2026, 2:27 AM EDT
Completed Phase 2 Interventional Results available

A Two-Part Study of BOTOX® Therapy for Ischemic Digits

NCT01309802
View directory record Official record
Conditions
Raynaud's Disease
Interventions
onabotulinum toxin type-A
Drug
Lead sponsor
Southern Illinois University
Other
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Springfield, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Oct 2, 2026, 2:27 AM EDT
Completed Phase 2 Interventional Results available

A Multi-Center Study of MYOBLOC for the Treatment of Sialorrhea in Parkinson's Disease Patients

NCT00515437
View directory record Official record
Conditions
Drooling
Interventions
Botulinum Toxin Type B (Myobloc), Matched placebo to Myobloc
Biological
Lead sponsor
Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
18
States / cities
Scottsdale, Arizona • Northridge, California • Oxnard, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 2, 2026, 2:27 AM EDT
Completed Phase 4 Interventional

Botox or Botox With Esophageal Dilation in Patients With Achalasia

NCT03654066
View directory record Official record
Conditions
Achalasia
Interventions
Botulinum toxin type A, Endoscope balloon dilator, Patient reported outcomes, Barium esophagram
Drug · Device · Other + 1 more
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 2, 2026, 2:27 AM EDT
Completed Phase 3 Interventional Results available

Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral Palsy

NCT02002884
View directory record Official record
Conditions
Cerebral Palsy, Spasticity
Interventions
IncobotulinumtoxinA (8 Units per kg body weight), IncobotulinumtoxinA (6 Units per kg body weight), IncobotulinumtoxinA (2 Units per kg body weight)
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
2 Years to 17 Years
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
6
States / cities
Gulf Breeze, Florida • Loxahatchee Groves, Florida • Savannah, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2021 · Synced Oct 2, 2026, 2:27 AM EDT
Completed Phase 2 Interventional

Clinical Trial to Evaluate the Safety and Efficacy of JTM201 to Treat Moderate or Severe Glabellar Lines

NCT06246552
View directory record Official record
Conditions
Glabellar Lines
Interventions
JTM201, Placebo
Biological
Lead sponsor
Jetema USA Inc.
Industry
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Manhattan Beach, California
Source: ClinicalTrials.gov public record
Updated Aug 29, 2025 · Synced Oct 2, 2026, 2:27 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Same-Day Combination of VI Peel and Botox for Correction of Sun Damage, Fine Lines and Wrinkles

NCT05162300
View directory record Official record
Conditions
Photoaging, Wrinkle, Sun Damaged Skin
Interventions
Same Day Intervention of VI Peel (Procedure) and Botulinum Toxin (Drug)
Combination Product
Lead sponsor
Vitality Institute Medical Products
Industry
Eligibility
30 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rancho Mirage, California
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 2, 2026, 2:27 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity

NCT04815967
View directory record Official record
Conditions
Spasticity, Cerebrovascular Accident, Multiple Sclerosis, Traumatic Brain Injury, Cervical Spinal Cord Injury, Cerebral Palsy
Interventions
Phase 2; Low Dose MYOBLOC (10,000 Units), Phase 2; High Dose MYOBLOC (20,000 Units), Phase 2; Placebo, Phase 3; MYOBLOC, Phase 3; Placebo
Drug
Lead sponsor
Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Downey, California • Boise, Idaho • Port Royal, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 2, 2026, 2:27 AM EDT
Completed Phase 3 Interventional Results available

A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent Headaches

NCT00168428
View directory record Official record
Conditions
Migraine Disorders
Interventions
Botulinum Toxin Type A, placebo (saline)
Biological · Other
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 65 Years
Enrollment
705 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Walnut Creek, California
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Oct 2, 2026, 2:27 AM EDT
Terminated Phase 2 Interventional Results available

Dysport in Vulvodynia Phase II Study

NCT03598777
View directory record Official record
Conditions
Vulvodynia
Interventions
Botulinum toxin type A, Placebo
Biological · Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
8
States / cities
Washington D.C., District of Columbia • Miami, Florida • Kansas City, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2021 · Synced Oct 2, 2026, 2:27 AM EDT